NCT05573217 is a clinical trial in Cell-free Methylation Markers, sponsored by National Taiwan University Hospital.

Who is sponsoring NCT05573217?

NCT05573217 is sponsored by National Taiwan University Hospital.

What condition does NCT05573217 study?

NCT05573217 studies Cell-free Methylation Markers.

Is NCT05573217 still recruiting?

NCT05573217 is currently status unknown. Last updated 10 October 2022.

Last reviewed 2022-10-10 · How we verify

NCT05573217

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Utility of Cell-free DNA Methylation Markers for Hepatocellular Carcinoma

Status unknown Last updated 10 October 2022

What this trial tests

trial in Cell-free Methylation Markers in 180 participants. Status unknown.

Timeline

1 July 2021

Primary endpoint
30 June 2023

30 June 2023

Quick facts

Lead sponsor	National Taiwan University Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	180
Start date	1 July 2021
Primary completion	30 June 2023
Estimated completion	30 June 2023
Sites	1 location across Taiwan

Conditions studied

Cell-free Methylation Markers — all drugs for Cell-free Methylation Markers →

Sponsor

National Taiwan University Hospital

Who can join

20 and older, any sex, with Cell-free Methylation Markers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The subjects of this study were patients with liver cancer diagnosed by physicians according to AASLD clinical criteria or pathological biopsy. Those who plan to receive systemic drug treatment for liver cancer in National Taiwan University Hospital include Nexavar, Lenvatinib, Avastin, Tecentriq, Strivarga, Cabometyx, Cyramza, Nivolunab, Pembrolizumab, and Yervoy. Weak and uncooperative patients were excluded from blood tests, which were performed with full informed consent for relevant tumor markers (AFP ,PIVKA-II and methylation analysis). The data are then counted and compared.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

DNA methylation in cell plasticity and malignant transformation in liver diseases.
Kim M, Delgado E, Ko S. · · 2023 · cited 15× · PMID 36535346 · DOI 10.1016/j.pharmthera.2022.108334

Verify or expand the search:

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05573217 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 10 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05573217.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing